Finally, we showed combining gemcitabine with an Akt pathway inhibitor (MK-2206) or Akt shRNA restores the sensitivity of pancreatic cancer cells to gemcitabine chemotherapy and improves the survival status of experimental mice. Here, AKT1 is linked to familial pancreatic carcinoma.